A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

This is a Phase I Dose-Escalation Study of BMS641988 in Patients with Castration-Resistant Prostate Cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Androgen Receptor Antagonists

Criteria

Inclusion Criteria:

• Advanced castration-resistant prostate carcinoma with progressive disease

• At least 4 weeks must have elapsed from major surgery

• Patient must be available for follow-up

• Adequate liver and kidney function

• Adequate blood values

Exclusion Criteria:

• Uncontrolled or significant heart disease

• History of seizures

• History of head injury, loss of consciousness, or stroke

• Patients undergoing alcohol withdrawal

• Any concurrent cancer

• A serious uncontrolled medical disorder or active infection

• Inability to swallow tablets